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Among 2,901 new smear-positive tuberculosis cases
in Ho Chi Minh City, Vietnam, 40 cases of treatment failure
and 39 relapsing cases were diagnosed. All initial and fol-
low-up Mycobacterium tuberculosis isolates of these case-
patients had (nearly) identical restriction fragment length
polymorphism patterns, and the Beijing genotype was a
significant risk factor for treatment failure and relapse (odds
ratio 2.8, 95% confidence interval 1.5 to 5.2).
T
he Beijing genotype is widespread in Asia (1–3), and
has been involved in outbreaks of multidrug-resistant
tuberculosis in various parts of the world, including Cuba,
Germany, Russia, and Estonia (4–7). The W strain, which
caused a large outbreak of multidrug-resistant tuberculosis
in the United States, is a variant of the Beijing genotype
(8–10). The Beijing genotype is emerging in Vietnam in
association with drug resistance in this region (11).
In a recent study on acquired drug resistance in Ho Chi
Minh City, Vietnam, drug resistance at time of enrollment
in the study was shown to be an important risk factor for
treatment failure and for relapse of tuberculosis after treat-
ment was completed successfully (12). We used the mate-
rials collected for this study to determine the extent to
which the Beijing genotype is a risk factor for treatment
failure or relapse.
The methods of this study have been described previ-
ously (12). In brief, 2,901 new case-patients with smear
results positive for Mycobacterium tuberculosis were
enrolled in Ho Chi Minh City, Vietnam, from August 1996
through July 1998. After a case was diagnosed at the dis-
trict tuberculosis center, a sputum sample from the case-
patient was sent to the reference laboratory, for a repeat
microscopy examination of the sputum smear to confirm
the diagnosis and to be stored at –20°C. All patients
received the standard regimen of the National Tuberculosis
Program, i.e., 2 months of streptomycin, isoniazid,
rifampicin, and pyrazinamide, followed by 6 months of
isoniazid and ethambutol (2SHRZ/6HE). When treatment
failure (defined as a positive sputum smear 5 or 8 months
after the onset of treatment) or relapse (defined as a posi-
tive sputum smear within 2 years after scheduled treatment
cessation) was noted, another sputum sample was collect-
ed, and both samples were cultured and tested for drug sus-
ceptibility with the proportion method. Restriction frag-
ment length polymorphism (RFLP) typing was performed
by using insertion element IS6110 as a probe (13,14) to
exclude reinfection and laboratory cross-contamination. 
A random sample of sputum samples was collected at
enrollment for culture and sensitivity testing from 10% of
patients who had not experienced treatment failure or
relapse (controls). This sample size would allow approxi-
mately two controls per case-patient. We performed
spoligotyping on the sputum samples of case-patients who
had experienced treatment failure or relapse and controls
to identify the samples that belonged to the Beijing geno-
type (15). The Beijing genotype was defined as strains
without spacers 1–34 and the presence of (at least 3) the
spacers 35–43 (16). 
Over the enrollment period, 6,113 new smear-positive
tuberculosis patients began a treatment regimen, 2,901 of
whom were included in the study. Slightly more men were
enrolled than women (age-adjusted odds ratio [OR] 1.2,
95% confidence interval [CI] 1.0 to 1.3), and enrollment
was particularly low in those >65 years of age (sex-adjust-
ed OR 0.3, 95% CI 0.2 to 0.4). Of the 2,901 enrolled
patients, 2,568 (88%) recovered, and 12 (0.4%) completed
treatment; in 125 (4.3%), treatment failed; 63 (2.2%) died;
53 (1.8%) were transferred out; and 80 (2.8%) did not
complete the study. Through December 1999, a total of
168 case-patients who experienced a relapse (6.5% of
those cured or with treatment completed) were identified.
Forty of 125 case-patients whose treatment failed and 39
of 168 case-patients who had a relapse had two positive
cultures with nearly identical RFLP patterns (12).
Spoligotyping results were available for 136 controls.
Case-patients were somewhat less likely than controls
to be female and tended to be somewhat older than con-
trols. However, these differences were not significant.
Primary drug resistance (in comparison with full suscepti-
bility) was a strong risk factor for treatment failure or
relapse with combined ORs of 3.4 for streptomycin
monoresistance, 4.2 for isoniazid monoresistance, and 23
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Health and the Environment, Bilthoven, the Netherlandsfor other susceptibility patterns (Table). The Beijing geno-
type was associated with treatment failure (OR 3.3 95% CI
1.3 to 8.3; p < 0.01) and relapse (OR 2.4 95% CI 1.0 to 5.7;
p < 0.05). In view of the small numbers and similar odds
ratios, these two groups were combined (OR 2.8, 95% CI
1.5 to 5.2) (Table). The association between the Beijing
genotype and treatment failure or relapse hardly changed
when taking into account primary drug resistance, age, and
sex (OR 3.2, 95% CI 1.4 to 7.1). We conclude that the
Beijing genotype is a risk factor for treatment failure and
relapse in Vietnam, irrespective of primary drug resistance.
This finding suggests that infections with Beijing genotype
strains are more persistent than infections with other M.
tuberculosis strains, which may explain the emergence of
Beijing genotype strains in this region (11).
This study had limited power to detect risk factors for
relapse and treatment failure, mainly because of the rela-
tively small numbers of case-patients in those categories.
Recruiting a larger number of controls could not change
this, since the selection of more than two controls per case,
while increasing workload, has relatively little impact on
the statistical power of the analysis. However, since the
association between the Beijing genotype and treatment
failure or relapse was strong, the association was signifi-
cant despite limited power.
Beijing genotype strains may have several selective
advantages over other genotypes of M. tuberculosis. In
many, but not all, areas where Beijing genotype strains are
prevalent, this genotype is associated with resistance to
antituberculosis drugs (17). The basis for this correlation
has so far not been disclosed. However, recent findings
indicated that exclusively in Beijing genotype strains,
mutations are present in putative mutator genes (18). This
finding may indicate that Beijing genotype strains have a
higher ability than other strains to allow particular critical
mutations in resistance genes, which enables them to
acquire resistance to the drugs used in a standard treatment
regimen. 
This enhanced flexibility due to alterations in the DNA
repair mechanism of Beijing genotype bacteria may also
play a role in the interaction with the host immune defense
system to deal with the less favorable conditions like expo-
sure to oxygen and nitrogen radicals in intracellular envi-
ronment. Extended research on the immunopathology
caused by M. tuberculosis strains of different genotypes in
a BALB/c mouse model has shown that most, but not all,
Beijing genotype strains cause a more severe pathology,
but a reduced immune response in comparison to other
genotypes of M. tuberculosis (19).
If Beijing genotype strains have a selective advantage
over other genotypes of M. tuberculosis, this may have
important implications for future tuberculosis control. The
enhanced capability to develop resistance and to interact
with the host immune defense system may facilitate the
spread of tuberculosis in Asia and in other areas. Currently,
a worldwide survey is being conducted to measure the
global spread of this genetically conserved group of M.
tuberculosis  strains and its association with resistance,
active transmission (young age), and other factors.
Although the conservation of Beijing genotype strains in
Asia is highly pronounced, the conserved population struc-
ture of M. tuberculosis in other high-prevalence areas such
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Table. Characteristics at enrollment of case-patients who experienced treatment failure and relapse and of controls who did not 
experience treatment failure, relapse, or die
a 
Crude  Adjusted
b  Adjusted
c 
Characteristic  Failure  Relapse  All case-patients  Controls  OR  95% CI  OR  95% CI  OR  95% CI 
Sex                     
Male  28  36  64  104  1        1   
Female  12  3  15  39  0.63  0.32 to 1.22      0.55  0.22 to 1.38 
Age group (y)                     
15–34  15  9  24  60  1        1   
35–54  22  25  47  72  1.63  0.90 to 3.0      2.0  0.90 to 4.6 
>55  3  5  8  11  1.82  0.65 to 5.1      2.4  0.60 to 9.9 
Genotype                     
Beijing  32  29  61  75  2.8  1.48 to 5.15  2.5  1.2 to 5.2  3.2  1.4 to 7.1 
Other  8  10  18  61  1    1    1   
Unknown        7             
Resistance pattern                     
Fully susc.  4  13  17  101  1    1    1   
S only  3  9  12  21  3.4  1.41 to 8.2  4.0  1.6 to 9.9  3.9  1.54 to 9.9 
H only  3  4  7  10  4.2  1.39 to 12  4.7  1.5 to 15  5.0  1.54 to 16 
Other  30
d  13
e  43  11  23  10.0 to 54  23  9.7 to 55  26  10.3 to 64 
TOTAL  40  39  79  143             
a OR, odds ratio; CI, confidence interval; susc., susceptible.
 
bAdjusted for genotype and resistance pattern.
 
cAdjusted for age, sex, genotype, and resistance pattern. 
dOf these 30, 12 had resistance to H and S, 1 to H, S, and E, 10 to H, R, and S, and 7 to H, R, S, E. 
eOf these 13, 11 had resistance to H and S, and 2 to H, S, and E. as Africa also merits further research on the possible devel-
opment of selective advantages.
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